Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

This evaluation was based on Revenue Per Employee (RPE) - a measure used by analysts to compare the productivity of companies in the same industry - and noted POZEN's RPE as $2.28 million. The other companies included in the top-five list were Columbia Laboratories, Depomed, ViroPharma and Pain Therapeutics.

As a next-generation pharmaceutical company, POZEN's philosophy is to own core capabilities and strategically partner for the rest. Its unique business model avoids some of the pitfalls of traditional drug development and commercialization, employing a small but expert team who lead the drug development strategy, partner selection and execution. The approach has delivered the approval of two self-invented products in two years - something almost no other small pharmaceutical company has done.